Cargando…

New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies

BACKGROUND: Numerous studies have reported the correlation between AXIN2 polymorphism and cancer risk, but the results seem not consistent. In order to get an overall, accurate and updated results about AXIN2 polymorphism and cancer risk, we conducted this study. METHODS: An updated analysis was per...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xi, Li, Yiming, Liu, Guodong, Wu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017882/
https://www.ncbi.nlm.nih.gov/pubmed/33794810
http://dx.doi.org/10.1186/s12885-021-08092-0
_version_ 1783674135895867392
author Li, Xi
Li, Yiming
Liu, Guodong
Wu, Wei
author_facet Li, Xi
Li, Yiming
Liu, Guodong
Wu, Wei
author_sort Li, Xi
collection PubMed
description BACKGROUND: Numerous studies have reported the correlation between AXIN2 polymorphism and cancer risk, but the results seem not consistent. In order to get an overall, accurate and updated results about AXIN2 polymorphism and cancer risk, we conducted this study. METHODS: An updated analysis was performed to analyze the correlation between AXIN2 polymorphisms and cancer risk. Linkage disequilibrium (LD) analysis was also used to show the associations. RESULTS: Seventy-two case-control studies were involved in the study, including 22,087 cases and 18,846 controls. The overall results showed rs11079571 had significant association with cancer risk (allele contrast model: OR = 0.539, 95%CI = 0.478–0.609, PAdjust = 0.025; homozygote model: OR = 0.22, 95% CI = 0.164–0.295, PAdjust< 0.001; heterozygote model: OR = 0.292, 95% CI = 0.216–0.394, PAdjust< 0.001; dominant model: OR = 0.249, 95% CI = 0.189–0.33, PAdjust< 0.001). The same results were obtained with rs1133683 in homozygote and recessive models (PAdjust< 0.05), and in rs35285779 in heterozygote and dominant models (PAdjust< 0.05). LD analysis revealed significant correlation between rs7210356 and rs9915936 in the populations of CEU, CHB&CHS, ESN and JPT (CEU: r(2) = 0.91; CHB&CHS: r(2) = 0.74; ESN: r(2) = 0.62, JPT: r(2) = 0.57), and a significant correlation between rs9915936 and rs7224837 in the populations of CHB&CHS, ESN and JPT (r(2)>0.5), between rs7224837 and rs7210356 in the populations of CEU, CHB&CHS, JPT (r(2)>0.5), between rs35435678 and rs35285779 in the populations of CEU, CHB&CHS and JPT (r(2)>0.5). CONCLUSIONS: AXIN2 rs11079571, rs1133683 and rs35285779 polymorphisms have significant correlations with overall cancer risk. What’s more, two or more polymorphisms such as rs7210356 and rs9915936, rs9915936 and rs7224837, rs7224837 and rs7210356, rs35435678 and rs35285779 have significant correlation with cancer susceptibility in different populations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08092-0.
format Online
Article
Text
id pubmed-8017882
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80178822021-04-05 New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies Li, Xi Li, Yiming Liu, Guodong Wu, Wei BMC Cancer Research Article BACKGROUND: Numerous studies have reported the correlation between AXIN2 polymorphism and cancer risk, but the results seem not consistent. In order to get an overall, accurate and updated results about AXIN2 polymorphism and cancer risk, we conducted this study. METHODS: An updated analysis was performed to analyze the correlation between AXIN2 polymorphisms and cancer risk. Linkage disequilibrium (LD) analysis was also used to show the associations. RESULTS: Seventy-two case-control studies were involved in the study, including 22,087 cases and 18,846 controls. The overall results showed rs11079571 had significant association with cancer risk (allele contrast model: OR = 0.539, 95%CI = 0.478–0.609, PAdjust = 0.025; homozygote model: OR = 0.22, 95% CI = 0.164–0.295, PAdjust< 0.001; heterozygote model: OR = 0.292, 95% CI = 0.216–0.394, PAdjust< 0.001; dominant model: OR = 0.249, 95% CI = 0.189–0.33, PAdjust< 0.001). The same results were obtained with rs1133683 in homozygote and recessive models (PAdjust< 0.05), and in rs35285779 in heterozygote and dominant models (PAdjust< 0.05). LD analysis revealed significant correlation between rs7210356 and rs9915936 in the populations of CEU, CHB&CHS, ESN and JPT (CEU: r(2) = 0.91; CHB&CHS: r(2) = 0.74; ESN: r(2) = 0.62, JPT: r(2) = 0.57), and a significant correlation between rs9915936 and rs7224837 in the populations of CHB&CHS, ESN and JPT (r(2)>0.5), between rs7224837 and rs7210356 in the populations of CEU, CHB&CHS, JPT (r(2)>0.5), between rs35435678 and rs35285779 in the populations of CEU, CHB&CHS and JPT (r(2)>0.5). CONCLUSIONS: AXIN2 rs11079571, rs1133683 and rs35285779 polymorphisms have significant correlations with overall cancer risk. What’s more, two or more polymorphisms such as rs7210356 and rs9915936, rs9915936 and rs7224837, rs7224837 and rs7210356, rs35435678 and rs35285779 have significant correlation with cancer susceptibility in different populations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08092-0. BioMed Central 2021-04-01 /pmc/articles/PMC8017882/ /pubmed/33794810 http://dx.doi.org/10.1186/s12885-021-08092-0 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Li, Xi
Li, Yiming
Liu, Guodong
Wu, Wei
New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies
title New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies
title_full New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies
title_fullStr New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies
title_full_unstemmed New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies
title_short New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies
title_sort new insights of the correlation between axin2 polymorphism and cancer risk and susceptibility: evidence from 72 studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017882/
https://www.ncbi.nlm.nih.gov/pubmed/33794810
http://dx.doi.org/10.1186/s12885-021-08092-0
work_keys_str_mv AT lixi newinsightsofthecorrelationbetweenaxin2polymorphismandcancerriskandsusceptibilityevidencefrom72studies
AT liyiming newinsightsofthecorrelationbetweenaxin2polymorphismandcancerriskandsusceptibilityevidencefrom72studies
AT liuguodong newinsightsofthecorrelationbetweenaxin2polymorphismandcancerriskandsusceptibilityevidencefrom72studies
AT wuwei newinsightsofthecorrelationbetweenaxin2polymorphismandcancerriskandsusceptibilityevidencefrom72studies